If your source water monitoring programme hasn’t been reviewed since the Drinking Water Directive transposition, it may not meet what auditors expect to see in 2026. Three regulatory developments have changed the baseline for what a compliant programme looks like. If you already have monitoring in place, its essential to ensure what you have is still sufficient.
Table of Contents
What’s Changed Regulatorily For Pharmaceutical Source Water
Drinking Water Directive 2020/2184 replaced the 1998 directive. It introduced new parameters, tighter limits, and a formal watch list for emerging contaminants. Potable water used as pharmaceutical source water must meet this standard at the point of use, not just at the point of supply.
PFAS limits came into force in January 2026. The directive sets 0.10 µg/L for the sum of 20 specific PFAS compounds and 0.50 µg/L for total PFAS. Standard compliance reports from Irish water utilities do not routinely include PFAS data. If you haven’t tested independently, you don’t yet know whether your supply is compliant.
The priority substances list is expanding. The Water Framework Directive is adding pharmaceuticals and bisphenols. Active pharmaceutical ingredients have been detected in Irish surface water. Bisphenol A is an endocrine disruptor with documented persistence in aquatic environments. What is monitored today is the beginning of a growing list.
Why Irish Source Water Requires Active Monitoring
Irish surface water is seasonal. A supply that tests clean in January may carry different contaminants by August. Algae bloom in warm months. Sediment loads rise after heavy rainfall. Agricultural runoff peaks in spring and autumn.
For a Quality or EHS Manager at an Irish pharmaceutical, cosmetics, or medtech facility, this variability is a direct GMP risk. A single annual snapshot does not capture it. A structured programme does.
What a Compliant Baseline Assessment Covers
A source water baseline is a full chemical and microbiological analysis of the potable supply as it arrives at site. For it to be defensible under audit, it needs to cover:
- All Drinking Water Directive 2020/2184 parameters: metals, nitrates, pesticides, disinfection by-products, microbiological indicators, turbidity, conductivity.
- Watch list substances: selected pharmaceuticals, endocrine-disrupting compounds, and the full PFAS suite. These require specific analytical methods and do not appear on standard utility reports.
- Site-specific contaminants of concern: a facility near agricultural land carries different risk than one near industrial activity or a coastal site. The baseline should reflect your specific location and supply.
All analysis must be conducted by an INAB-accredited laboratory. Accreditation means the data is independently validated against international standards and is an essential part of GMP audits.
What an Ongoing Monitoring Programme Looks Like in Practice
A baseline tells you what the water looked like on the day of sampling. Ongoing monitoring tells you what’s changing and gives you lead time to act.
A structured programme typically involves:
- Quarterly or six-monthly sampling events, planned in advance.
- Sample collection by trained personnel, with full chain-of-custody documentation.
- Accredited laboratory analysis, with results compared against baseline and prior rounds.
- Trend reporting, when something changes, you have data showing when it started, how fast it’s moving, and whether it’s approaching a threshold.
Our programmes aim to help Irish companies move from reactive crisis management to proactive protection.
Working With Southern Scientific
Southern Scientific works with Irish pharmaceutical, cosmetics, and medtech sites on source water baseline assessments and ongoing monitoring programmes. Our laboratory is INAB-accredited and analyses against the full DWD 2020/2184 parameter set, including PFAS, watch list substances, and site-specific contaminants.
